Metropolis Healthcare Ltd

Metropolis Healthcare Ltd

Metropolis Healthcare Ltd will participate in a Q2FY27 earnings conference call on November 04, 2026, to discuss its financial results for the quarter and half year ended September 30, 2026.

Metropolis Healthcare Ltd

Metropolis Healthcare Ltd has scheduled a board meeting on November 3, 2026, to consider and approve unaudited financial results for the quarter and half year ended September 30, 2026, and to declare an interim dividend for the financial year 2026-27.

Metropolis Healthcare Ltd

Metropolis Healthcare Ltd has allotted 9,516 equity shares under the Metropolis-Restrictive Stock Unit Plan, 2020, at an exercise price of INR 2 per share, aggregating to INR 19,032. The shares will rank pari-passu with existing equity shares and are subject to a 50% lock-in for 1 year from the date of allotment.

Metropolis Healthcare Ltd

Metropolis Healthcare Ltd has submitted a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming compliance for the quarter ended September 30, 2026.

Metropolis Healthcare Ltd

Metropolis Healthcare Ltd has announced a business update for Q2FY27, reporting a 15% revenue growth YoY, driven by double-digit patient and test volume growth, improved realizations, and a change in product mix. The company's TruHealth Wellness and Specialty segments emerged as the fastest-growing segments during the quarter. EBITDA margins have improved meaningfully on both YoY and QoQ basis, driven by operating leverage and efficiency gains.

Metropolis Healthcare Ltd

Metropolis Healthcare Ltd has closed its trading window for designated persons and their immediate relatives from September 29, 2026, until 48 hours after the declaration of its financial results for the quarter and half year ending September 30, 2026.

Metropolis Healthcare Ltd

Metropolis Healthcare Ltd's management team discussed the company's 45-year journey, growth, and future plans during an investor and analyst meet on August 27, 2026. The company has 209 laboratories and 5,000 plus centers across 750 towns in India and 5 international markets. Revenue for the last year was INR1,646 crores, with a distribution of 50% from the West, 27% from the South, 18% from the North, and 5% from the East. The North India region showed significant growth in Q1.

Metropolis Healthcare Ltd

Metropolis Healthcare Ltd has made an announcement regarding the availability of the audio recording of the Investors & Analyst Meet held on August 27, 2026, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Metropolis Healthcare Ltd

Metropolis Healthcare Ltd has transferred its External Quality Assessment Services Business Division to its subsidiary Metropolis Quality Solutions Private Limited on a slump sale basis for INR 1.25 crore, with the consideration being discharged by issuing equity shares of MQSPL to the company.

Metropolis Healthcare Ltd

Metropolis Healthcare Ltd has released an investor presentation for its Investors & Analyst Meet, outlining its three-year directional ambitions, revenue mix, and growth strategy.

Metropolis Healthcare Ltd

Metropolis Healthcare Ltd has informed about the approval of Optionally Convertible Redeemable Preference Shares (OCRPS) issuance by its wholly owned subsidiary, Metropolis Quality Solutions Private Ltd. The OCRPS will be converted into equity shares in tranches over 6 years, with Dr. Puneet Kumar Nigam, a former Chief Quality Officer, as the proposed buyer.

Metropolis Healthcare Ltd

Metropolis Healthcare Ltd has announced the schedule for an Analyst / Institutional Investor Meeting on August 27, 2026, to discuss publicly available information. The meeting is a group meeting and no unpublished price sensitive information will be discussed.

Metropolis Healthcare Ltd

Metropolis Healthcare Ltd has announced the Scrutinizer's Report for the 26th Annual General Meeting, confirming the voting results through remote e-voting and electronic voting. The report ensures fair and transparent voting processes, as per the Companies Act, 2013, and SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The meeting was held on August 18, 2026, through Video Conferencing/OAVM, and the voting results are available on the company's website.

Metropolis Healthcare Ltd

Metropolis Healthcare Ltd held its 26th Annual General Meeting (AGM) on August 18, 2026, through Video Conferencing. The meeting approved the audited standalone and consolidated financial statements for FY 2025-26, confirmed the payment of interim dividends, and re-appointed a director. The company also appointed Deloitte Haskins & Sells Chartered Accountants LLP as its statutory auditors.

Metropolis Healthcare Ltd

Metropolis Healthcare Ltd's promoter group has sold 10,50,000 shares through open market sale on August 11, 2026, representing 0.51% of the company's shareholding.

Metropolis Healthcare Ltd

Duru Shah Family Trust, a promoter group entity of Metropolis Healthcare Ltd, has sold 10,50,000 equity shares of the company through open market sale on August 11, 2026, representing 0.51% of the company's shareholding.

Metropolis Healthcare Ltd

Metropolis Healthcare Ltd has announced the transcript of its Q1 FY27 earnings conference call, highlighting the Indian diagnostics industry's structural growth opportunities and the company's capabilities in specialty testing.

Metropolis Healthcare Ltd

Metropolis Healthcare Ltd has announced the availability of the audio recording of its earnings conference call for Q1 FY27, held on August 05, 2026.

Metropolis Healthcare Ltd

Metropolis Healthcare Ltd has published its unaudited financial results for the quarter ended June 30, 2026, in newspapers 'The Free Press Journal' and 'Navshakti'.

Metropolis Healthcare Ltd

Metropolis Healthcare Ltd has released its Q1 FY27 investor presentation, highlighting revenue growth of 17% YoY, EBITDA growth of 27% YoY, and PAT growth of 26% YoY. The company has also reported double-digit patient and test volume growth, with B2C revenue up 18% YoY and B2B revenue up 15% YoY.